格隆汇2月6日丨药明康德(603259.SH)在投资者互动平台表示，Chemistry 42属于另一家生物科技公司， 和药明康德无关。公司历来不自行开发新药，也没有用AI来开发新药。 ...

Core Viewpoint - The article discusses the recent performance of the Hong Kong stock market, highlighting the rotation between growth and value styles, and the impact of external market fluctuations on local indices [2][8]. Market Performance - The overall market experienced a slight decline, closing at 3.9 stars [1]. - Large-cap stocks fell, while mid and small-cap stocks showed minor fluctuations [2]. - Growth styles, particularly in the ChiNext, initially rose but ended the day lower [2]. Style Rotation - The article notes that the Hong Kong market has seen several style rotations since September 2024, with growth styles being strong from September 2024 to September 2025, where tech stocks' earnings doubled year-on-year, marking the fastest growth in five years [2]. - In contrast, value styles, such as the Hang Seng Dividend Low Volatility Index, saw a more modest increase of around 30% during the same period [2]. - From September 2025 onwards, growth styles faced a correction, with the tech index retreating approximately 19% [2]. Investment Strategy - The article emphasizes the importance of balancing investments between growth and value styles, adjusting allocations based on valuation metrics [10][11]. - It suggests that during periods of market fluctuations, investors should buy undervalued assets and sell overvalued ones, maintaining a patient approach during less volatile times [12][13]. Valuation Insights - The article provides a summary of the valuation metrics for various Hong Kong indices, indicating that the current star rating for the Hong Kong market is around 3 stars [14][16]. - It includes specific valuation data for indices such as the H-share Index and the Hang Seng Index, highlighting their price-to-earnings ratios and dividend yields [15].

证监会2月6日消息，1月7日，深圳市亚辉龙生物科技股份有限公司披露签署战略合作框架协议的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙立案调 查。 该公告披露后，引发媒体报道及市场关注。经上交所督促，公司于当晚又发布《关于自愿披露签署战略合作框架协议的补充公告》称，脑机星链目前在研 产品的技术路线为非侵入式技术路径，尚无侵入式技术布局，且脑电采集分析仪等产品尚未进入注册申报阶段，有的产品尚处于早期研发阶段或临床前阶 段。 上交所表示，当前，"脑机接口"为市场热点概念，投资者高度关注。特别是，公司股价当日（1月6日）收盘上涨6.52%、成交量较前一个交易日增长 299%，公司披露涉及热点相关信息尤其应当审慎，确保相关信息披露真实、准确、完整，避免对投资者产生误导。公司相关公告对合作方脑机星链技术 路径是否包含侵入式的表述前后不一致，也未就合作协同性、可行性以及后续合作不确定性等投资者关注的重点事项进行充分提示风险，信息披露不准 确、不完整。 公司上述行为违反了《上海证券交易所科创板股票上市规则》相关条款，以及《上海证券交易所科创板上市公司自律监管指引第2号——自愿信息披露》 等有关规定。公司时任董事会秘书王鸣阳作 ...

Group 1 - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yahui Long Biotechnology Co., Ltd. (Yahui Long) for allegedly misleading statements in their announcement regarding a strategic cooperation framework agreement [1] - Yahui Long signed a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd. (Brain Machine Starlink), which has drawn media and market attention due to the current popularity of the "brain-computer interface" concept [2][3] - The Shanghai Stock Exchange (SSE) issued a regulatory warning to Yahui Long, highlighting inconsistencies in the company's disclosures about the technology paths of Brain Machine Starlink and the status of their products, which could mislead investors [3] Group 2 - Multiple companies have faced regulatory warnings for "hitching a ride" on market trends, with the CSRC investigating cases of misleading statements, including Ningbo Tianpu Rubber Technology Co., Ltd. and Ningbo Rongbai New Energy Technology Co., Ltd. [4] - The SSE has also issued warnings to companies like Shenzhen Yingjixin Technology Co., Ltd. and Jiangxi Woge Optoelectronics Group Co., Ltd. for failing to accurately disclose the status and impact of their products, which could mislead investors [5][8] - The regulatory actions aim to ensure that companies provide truthful, accurate, and complete information to maintain market integrity and protect investors [8]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. (referred to as Yahui Long) has disclosed a strategic cooperation framework agreement, which is suspected of misleading statements. The regulatory authority has initiated an investigation into Yahui Long to ensure the healthy development of the market [2] Group 1 - Yahui Long signed a strategic cooperation framework agreement on January 7, 2026 [2] - The announcement regarding the agreement has raised concerns about potential misleading statements [2] - The regulatory authority has launched an investigation into Yahui Long to address these concerns [2]

近日，我会已对亚辉龙立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 据证监会2月6日消息，2026年1月7日，深圳市亚辉龙生物科技股份有限公司(简称亚辉龙)披露签署战略 合作框架协议的公告，涉嫌误导性陈述。 ...

Core Viewpoint - He Yuan Bio (688765.SH), a pre-profit biopharmaceutical company listed on the STAR Market, is facing significant challenges including expanding losses, tight cash flow, uncertainties regarding the commercialization of its core products, and controversies over information disclosure, making it a typical case for observing the survival status of unprofitable STAR Market enterprises [1][7]. Group 1: Continuous Losses and Cash Flow Pressure - He Yuan Bio expects a net profit loss of between 143 million to 167 million yuan for 2025, with cumulative losses exceeding 480 million yuan over the past three years, bringing total losses over four years to over 600 million yuan [2][8]. - The company's main product, recombinant human albumin, accounts for about 80% of revenue, but its selling price has declined from 151.46 yuan per gram in 2022 to 112.69 yuan in the first half of 2025, leading to a continuous decrease in gross margin [2][8]. - The company has incurred over 60 million yuan in litigation-related expenses with Ventria Bioscience, further eroding profits, while cash flow from operating activities has been negative for years, with cash reserves plummeting from 388 million yuan in 2022 to 75 million yuan by September 2025 [2][8]. Group 2: Main Business and Cost Control Challenges - The company attributes its losses to its core product, Aofumin (recombinant human albumin injection), being in the market introduction phase and production ramp-up, yet R&D expenditures have reportedly decreased in 2024 [3][9]. - High professional service fees in management expenses due to litigation reflect challenges in cost control and risk management [3][9]. - The company purchased liability insurance for all directors and executives shortly after its IPO, indicating a self-warning about operational risks despite the relatively small amount of expenditure, raising market scrutiny over its financial discipline [3][9]. Group 3: Core Product Commercialization and Information Disclosure Concerns - The future of He Yuan Bio largely depends on the commercialization prospects of its core product HY1001, but revenue forecasts for 2026 to 2030 have been quietly reduced from 7.255 billion yuan to 5.470 billion yuan, a cut of nearly 1.8 billion yuan, without clear explanation in the prospectus [4][10]. - The product lacks commercial validation, having experienced serious adverse events during Phase I clinical trials, raising concerns about its market readiness [4][10]. - Discrepancies in information disclosure have led to doubts about the rigor and transparency of the company's forecasts, which could continue to affect investor confidence in a market increasingly focused on R&D progress and commercialization capabilities [4][10]. Group 4: Industry Reflection - The case of He Yuan Bio reflects the common predicament faced by many unprofitable STAR Market companies, which must balance expanding losses, tight cash flow, uncertainties in product commercialization, and regulatory compliance in information disclosure [5][11]. - While the STAR Market's fifth set of standards has opened financing avenues for hard tech companies, sustainable business models, robust financial controls, and transparent disclosures remain essential to meet market and investor expectations [5][11]. - For He Yuan Bio, accelerating the commercialization of its core products, improving cash flow, and rebuilding market trust are critical challenges that must be addressed [5][11].

Core Viewpoint - The "15th Five-Year Plan" is expected to provide clear direction and policy support for the capital market, with a focus on traditional industry upgrades, emerging industry demand expansion, and thematic investments in frontier industries [1] Macro Analysis: Opportunities in Financial Assets - The liquidity environment is expected to remain relatively loose both globally and domestically, providing opportunities across various financial assets, with a particular emphasis on the A-share equity market [2] - Current A-share market valuations are considered reasonable based on historical rolling returns, suggesting that the market is not overly expensive [2] - Two core supporting factors for the A-share market include a friendly liquidity environment and an anticipated upward trend in the profit cycle due to improved supply-demand dynamics [2] Trend Assessment: Technological Self-Reliance - The "15th Five-Year Plan" emphasizes technological self-reliance as a strategic task, highlighting the importance of technological innovation and productivity improvement for sustainable economic development [4] Insight into Opportunities: Three Structural Directions - The "15th Five-Year Plan" outlines three key investment directions: 1. Traditional industries such as chemicals, shipbuilding, and metallurgy are expected to enhance profitability through supply-side policies and optimization [5][6] 2. Emerging industries like artificial intelligence and energy storage are projected to experience sustained demand growth, leading to rapid development [6] 3. Frontier industries, including embodied intelligence and quantum technology, are seen as having significant growth potential and should be monitored for breakthroughs in basic scientific research [6] Rational Layout: Understanding Industry Trends - Investors are advised to recognize industry trends and avoid frequent timing based on short-term fluctuations, particularly in the high-growth and high-volatility technology sector [7] - The investment strategy should focus on understanding industry development trends and adjusting strategies only when substantial changes occur in the underlying fundamentals [7]

Core Viewpoint - The stock of Suzhou Fengbei Biotechnology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on February 4 and 5, 2026, prompting a review of the situation by the company [2][4]. Group 1: Stock Trading Abnormality - The company's stock price showed a significant deviation, with a cumulative increase of over 20% on February 4 and 5, 2026, classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][4]. - The company conducted a self-examination and confirmed that there were no undisclosed significant matters apart from those already disclosed [2][6]. Group 2: Operational Status - The company reported that its production and operational activities are normal, with no significant changes in market conditions or industry policies, and no substantial fluctuations in production costs or sales [5]. - There are no major undisclosed matters involving the company, including significant asset restructuring, share issuance, acquisitions, or other major corporate actions [6]. Group 3: Media and Market Rumors - The company found no media reports, market rumors, or trending concepts that could significantly impact its stock price during the abnormal trading period [7]. - Company executives and major shareholders did not engage in buying or selling the company's stock during the period of abnormal trading fluctuations [8].

Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. experienced significant stock price fluctuations, with a cumulative closing price increase exceeding 20% over two consecutive trading days, triggering abnormal trading conditions as per Shanghai Stock Exchange regulations [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price increased by more than 20% cumulatively on February 4 and 5, 2026, indicating abnormal trading activity [2][4]. - The company confirmed that there are no undisclosed significant matters affecting the stock price, following inquiries with its controlling shareholder and actual controller [6][8]. Group 2: Company Operations and Major Events - The company reported that its production and operational activities are normal, with no significant changes in market conditions, industry policies, production costs, or sales [5]. - There are no major undisclosed events or plans, such as asset restructuring or significant business collaborations, that could impact the company [6]. Group 3: Media and Market Rumors - The company found no media reports, market rumors, or trending concepts that could significantly affect its stock price [7]. Group 4: Board and Management Assurance - The board of directors confirmed that there are no undisclosed matters that should have been reported according to the Shanghai Stock Exchange regulations, and previous disclosures do not require correction or supplementation [11].